NCT03298542View on ClinicalTrials.gov

A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 16, 2017

Primary Completion Date

December 21, 2020

Study Completion Date

June 1, 2021

Conditions
Pre-Symptomatic Type 1 Diabetes
Interventions
DRUG

Golimumab

Participants will receive subcutaneous golimumab for 26 weeks, where doses will be based on weight and/or body surface area.

DRUG

Placebo

Matching placebo to golimumab.

Trial Locations (8)

19104

Children's Hospital of Philadelphia, Philadelphia

20520

Turku University Hospital, Turku

22903

University of Virginia, Charlottesville

80045

UC Denver-Colorado Barbara Davis Center, University of Colorado SOM Pediatric Endocrinology, Aurora

FI-90014

Oulu University Hosp. Oulu, Oulu

FI-33521

Tampere University Hospital, Tampere

SE 58185

Linkoping University Hospital, Linköping

205 02

Lund University Hospital/Skåne, Lund/Malmo

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03298542 - A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes | Biotech Hunter | Biotech Hunter